L-carnitine in tuberculosis

Evaluation of l- carnitine prophylaxis on antituberculosis drugs-induced hepatotoxicity

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201102273449N3

Enrollment

100

Registered

2011-04-18

Start date

2011-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis. Tuberculosis

Interventions

Intervention 1: l-carnitine 10cc,BID,PO for 4weeks. Intervention 2: l-carnitine placebo ,10cc,BID,PO for 4weeks.

Treatment - Drugs

Placebo

l-carnitine 10cc,BID,PO for 4weeks

l-carnitine placebo ,10cc,BID,PO for 4weeks

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:Tuberculosis diagnosis according to microbiological,clinical,pathological and epidemiological evidences and anti- tuberculosis treatment, Consent form signing 3.No history of carnitine or multivitamin use during last 8week, Age >18y, No history of Anti-Epileptic drugs use 6.No history of renal or liver disease,No history of thyroid abnormalities -Exclusion criteria: Having adverse drug reaction(eg.hypertention,diaherra), Patient's refusal to participate in the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hepatotoxicity. Timepoint: At the begining of study and after 4weeks. Method of measurement: Liver enzyme and clinical sign and symptom.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026